Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Antisense Therapeutics Ltd. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, ALLEN, SARAH ELIZABETH, who is the busiest examiner with 1 pending action. The matter is located in 1 distinct art unit, indicating a focused technical inquiry.
The company currently has 1 pending office action under review, which is handled by 1 distinct examiner. This creates a centralized prosecution environment where ALLEN, SARAH ELIZABETH is the sole individual reviewing the pending intellectual property. The activity is confined to 1 distinct art unit, suggesting that the company's current biotechnology innovation falls into a specific administrative niche.
For the practitioner, the presence of 1 distinct examiner and 1 distinct art unit means that the prosecution strategy must be highly personalized. Success for the 1 pending office action depends entirely on addressing the specific concerns of ALLEN, SARAH ELIZABETH. This concentration simplifies the management of the portfolio but increases the impact of the examiner's individual decision-making on the company's overall patent goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, SARAH ELIZABETH | 1 | 56.7% | +33.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18623963 | THERAPEUTIC USES AND METHODS | ALLEN, SARAH ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18623963 | THERAPEUTIC USES AND METHODS | ALLEN, SARAH ELIZABETH | 1637 | §103§112DP | Non-Final OA | — | Pending | Apr 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAntisense Therapeutics Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sarah Elizabeth Allen has the most, with 1 of Antisense Therapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
